CUPERTINO, Calif., Oct. 17, 2019 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) announced today that it will be
presenting at two upcoming investor conferences focused on
non-alcoholic steatohepatitis (NASH): the H.C. Wainwright
3rd Annual NASH Investor Conference, to be held in
New York City on Monday, October 21, 2019 and the B. Riley
"NASH-ing in, Let's All Dig in on What's to Come at AASLD'19 and
EASL'20" NASH symposium, to be held in San Francisco on Thursday, October 24, 2019.
Institutional investors that are attending the conferences may
request one-on-one meetings with DURECT management through the
respective conference coordinators.
HC Wainwright
3rd Annual NASH Investor Conference
Details:
|
Date:
|
Monday, October 21,
2019
|
Time:
|
3:40 p.m.
EDT
|
Location:
|
St. Regis Hotel in
New York City
|
Webcast:
|
A live audio webcast
of the presentation will be available by accessing
|
http://wsw.com/webcast/hcw6/drrx/ or https://investors.durect.com.
If you are unable to participate during the live webcast, the call
will be archived on DURECT's website in the "Event Calendar" of the
"Investors" section.
|
|
B. Riley NASH
Symposium Panel Details:
|
Panel:
|
Two New Kids on The
Block and How They Could Break Away from the Crowd?
|
Date:
|
Thursday, October 24,
2019
|
Time:
|
Noon – 12:25 p.m.
PDT
|
Location:
|
Hotel Zelos in San
Francisco
|
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical entity
in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally bioavailable
small molecule, DUR-928 has been shown in preclinical studies to
play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may include
acute organ injury such as alcoholic Hepatitis (AH) and acute
kidney injury (AKI), chronic hepatic diseases such as nonalcoholic
steatohepatitis (NASH), and inflammatory skin conditions such as
psoriasis and atopic dermatitis. DURECT's advanced oral and
injectable delivery technologies are designed to enable new
indications and enhanced attributes for small-molecule and biologic
drugs. Key product candidates in this category include
POSIMIR® (bupivacaine extended-release solution), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery, a
long-acting injectable SABER-based HIV investigational product
being developed with Gilead. For more information about DURECT,
please visit www.durect.com.
DURECT Forward-Looking Statement
This press release includes forward-looking statements,
including the potential use of DUR-928 to treat AH, AKI, chronic
hepatic diseases such as NASH, and inflammatory skin disorders such
as psoriasis and atopic dermatitis, as well as statements regarding
the use of POSIMIR to treat post-surgical pain and the development
of a SABER-based HIV investigational product. These forward-looking
statements involve risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not
limited to, the risk of potential adverse effects arising from the
testing or use of DUR-928, the risk that the FDA may not approve
the POSIMIR NDA, our ability to meet milestones in the development
of an injectable SABER-based HIV investigational product and the
risk that Gilead will terminate the development of this product,
our ability to avoid infringing patents held by other parties and
secure and defend patents of our own patents, and our ability to
manage and obtain capital to fund our operations and expenses.
Further information regarding these and other risks is included in
DURECT's Form 10-Q filed with the Securities and Exchange
Commission on August 2, 2019 under
the heading "Risk Factors."
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-two-upcoming-nash-investor-conferences-300940891.html
SOURCE DURECT Corporation